Literature DB >> 14724427

Alloantibody and xenoantibody cross-reactivity in transplantation.

D K C Cooper1, Y-L Tseng, S L Saidman.   

Abstract

The recent availability of pigs homozygous for alpha1,3-galactosyltransferase gene knockout, and improved immunosuppressive regimens that prevent an elicited antibody response, are expected to contribute to significantly increased survival of pig organs transplanted into primates, bringing clinical trials of xenotransplantation closer. Patients highly sensitized to human leukocyte antigens, who may be precluded from obtaining a human donor organ, would be one group that might benefit from xenotransplantation. However, there have been few studies on whether there is cross-reactivity of anti-human leukocyte antigen antibodies with pig antigens. What data there are suggest that such cross-reactivity exists and that this may be detrimental to the outcome after transplantation of a pig organ. Neither is it known whether sensitization after a pig xenograft would preclude subsequent allotransplantation, although the data available suggest that this will not be the case. Further investigation on allo- and xenoantibody cross-reactivity is required.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14724427     DOI: 10.1097/01.TP.0000105116.74032.63

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  20 in total

Review 1.  The role of complement in the early immune response to transplantation.

Authors:  Steven H Sacks; Wuding Zhou
Journal:  Nat Rev Immunol       Date:  2012-05-25       Impact factor: 53.106

Review 2.  Genetically-engineered pigs as sources for clinical red blood cell transfusion: What pathobiological barriers need to be overcome?

Authors:  Benjamin Smood; Hidetaka Hara; Leah J Schoel; David K C Cooper
Journal:  Blood Rev       Date:  2019-01-28       Impact factor: 8.250

Review 3.  Selection of Patients for Initial Clinical Trials of Solid Organ Xenotransplantation.

Authors:  David K C Cooper; Martin Wijkstrom; Sundaram Hariharan; Joshua L Chan; Avneesh Singh; Keith Horvath; Muhammad Mohiuddin; Arielle Cimeno; Rolf N Barth; John C LaMattina; Richard N Pierson
Journal:  Transplantation       Date:  2017-07       Impact factor: 4.939

Review 4.  Chronic dialysis in patients with end-stage renal disease: Relevance to kidney xenotransplantation.

Authors:  Abhijit Jagdale; David K C Cooper; Hayato Iwase; Robert S Gaston
Journal:  Xenotransplantation       Date:  2018-11-20       Impact factor: 3.907

Review 5.  Islet cell xenotransplantation: a serious look toward the clinic.

Authors:  Kannan P Samy; Benjamin M Martin; Nicole A Turgeon; Allan D Kirk
Journal:  Xenotransplantation       Date:  2014-05-08       Impact factor: 3.907

6.  Frankenswine, or bringing home the bacon: How close are we to clinical trials in xenotransplantation?

Authors:  David Kc Cooper
Journal:  Organogenesis       Date:  2008-01       Impact factor: 2.500

Review 7.  The role of genetically engineered pigs in xenotransplantation research.

Authors:  David K C Cooper; Burcin Ekser; Jagdeece Ramsoondar; Carol Phelps; David Ayares
Journal:  J Pathol       Date:  2015-10-07       Impact factor: 7.996

Review 8.  Pig liver xenotransplantation as a bridge to allotransplantation: which patients might benefit?

Authors:  Burcin Ekser; Bruno Gridelli; A Joseph Tector; David K C Cooper
Journal:  Transplantation       Date:  2009-11-15       Impact factor: 4.939

Review 9.  Current status of pig kidney xenotransplantation.

Authors:  Hayato Iwase; Takaaki Kobayashi
Journal:  Int J Surg       Date:  2015-08-22       Impact factor: 6.071

Review 10.  Xenotransplantation: immunological hurdles and progress toward tolerance.

Authors:  Adam Griesemer; Kazuhiko Yamada; Megan Sykes
Journal:  Immunol Rev       Date:  2014-03       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.